天眼查资料显示，华纳药厂成立于2001年04月30日，注册资本9380万人民币，法定代表人黄本东，注册 地址为湖南浏阳生物医药园区。主营业务为化学原料药、化学药制剂和中药制剂的研发、生产与销售。 目前，公司董事长为黄本东，董秘为乔桥，员工人数为1238人，实际控制人为黄本东。 雷达财经 文|冯秀语 编|李亦辉 9月7日，华纳药厂（证券代码：688799）发布公告称，其控股子公司上海致根医药科技有限公司通过增 资扩股引入战略投资者的事项已取得进展。根据公告，致根医药按照投前估值4亿元人民币获得了共计 6,999.8684万元的投资。此次增资事宜已经过公司董事会、监事会及股东大会审议通过，增资金额合计 不超过7,000万元。 目前，致根医药已完成工商变更登记，并取得了新的营业执照。 公司参股公司13家，包括湖南华纳大药厂手性药物有限公司、湖南华纳大药厂天然药物有限公司、湖南 华纳大药厂科技开发有限公司、湖南华纳大药厂医贸有限公司、湖南美和美诺生物技术有限公司等。 在业绩方面，公司2024年至2025(Q2)年营业收入分别为14.13亿元、3.36亿元和7.14亿元，同比分别增 长-1.38%、-9.83%和-3. ...

Group 1 - Junshi Biosciences' anti-IL-17A monoclonal antibody (JS005) achieved positive results in a Phase III clinical trial for moderate to severe plaque psoriasis, with both primary and key secondary endpoints showing statistical significance and clinical relevance. The company plans to submit a marketing authorization application soon [1] - Warner Pharmaceuticals announced that its subsidiary, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., will introduce strategic investors for a capital increase not exceeding 70 million yuan, which will support the clinical trials of its innovative drugs, including ZG-001 and ZG-002 [2] - Sunflower is planning a major asset restructuring to acquire controlling stakes in Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd., aiming to enhance its competitiveness in the pharmaceutical sector and enter the new materials field [3] Group 2 - Huaxi Biological's controlling shareholder, Huaxi Xinyu Investment Co., Ltd., plans to increase its stake in the company with an investment of no less than 200 million yuan and no more than 300 million yuan, having already exceeded the lower limit of the planned increase. This move reflects confidence in the company's long-term development [4] - Eli Lilly has initiated a Phase I clinical trial for its weight loss drug LY4064912, which has no disclosed mechanism target yet. This step underscores the company's commitment to the metabolic field and aims to solidify its leading position in the obesity treatment market [5]

湖南华纳大药厂股份有限公司于2025年4月18日召开董事会及监事会，审议通过控股子公司上海致根医 药科技有限公司增资扩股引入战略投资者的议案，并于2025年5月12日经年度股东大会批准。致根医药 本轮引入战略投资者，投资方按投前估值4亿元人民币，合计投资6,999.8684万元，以认购增资方式投 入。近日，致根医药已完成工商变更登记，取得上海市浦东新区市场监督管理局颁发的《营业执照》。 变更后注册资本为人民币205.5572万元，公司名称、住所、法定代表人等信息不变。经营范围包括技术 服务、技术开发、生物化工产品研发、医学研究等。华纳药厂董事会保证公告内容真实、准确、完整， 无虚假记载、误导性陈述或重大遗漏。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：9月5日主力资金净流出536.76万元，游资资金净流出1055.97万元，散户资金 净流入1592.73万元。 来自公司公告汇总：控股子公司上海致根医药完成增资扩股工商变更，投前估值4亿元，战略投资 者合计投资6,999.8684万元。 9月5日主力资金净流出5 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2025-075 湖南华纳大药厂股份有限公司 关于控股子公司增资扩股引入战略投资者 暨关联交易的进展公告 公司名称：上海致根医药科技有限公司 统一社会信用代码：91310115MA7DDX598D 类型：有限责任公司（自然人投资或控股） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次交易概述 湖南华纳大药厂股份有限公司（以下简称"公司"、"华纳药厂"）于 2025 年 4 月 18 日召开第四届董事会第一次会议及第四届监事会第一次会议、于 2025 年 5 月 12 日召开 2024 年年度股东大会，审议通过了《关于控股子公司增资扩股 引入战略投资者暨关联交易的议案》，同意控股子公司上海致根医药科技有限公 司（以下简称"致根医药"）引入战略投资者进行增资扩股，增资金额合计不超 过 7,000 万元。具体内容详见公司于 2025 年 4 月 22 日在上海证券交易所网站 （www.sse.com.cn）披露的《湖南华纳大药厂股份有限公司关于控股子公司增资 扩股引 ...

Core Viewpoint - Warner Pharmaceuticals reported a decline in revenue and net profit for the first half of 2025, influenced by market conditions, while actively developing innovative drug candidates with significant potential [1][2][3] Financial Performance - The company achieved revenue of 714 million yuan, a year-on-year decrease of 3.37% [1] - The net profit attributable to shareholders was 71.12 million yuan, down 36.95% year-on-year; excluding stock incentive expenses, the net profit was 90.36 million yuan, a decrease of 19.89% [1] Innovative Drug Development - ZG001, an antidepressant, is in Phase IIa clinical trials, showing excellent safety with no severe adverse reactions and rapid absorption [1] - ZG002, a new drug for autoimmune diseases, demonstrated 2-4 times the in vitro activity of the already marketed BMS-986165 and is set to enter Phase I clinical trials for moderate to severe plaque psoriasis [2] - The company is advancing its traditional Chinese medicine pipeline, including the innovative drug Qianqing Granules, which has shown good safety and stable efficacy in Phase II trials and is moving to Phase III trials [2] R&D and Regulatory Progress - The company made significant progress in generic and raw material drug development, obtaining six drug registration approvals and five raw material approvals during the reporting period [2] - The company has submitted nine formulation product registration applications and completed three consistency evaluations [2] Profit Forecast - Revenue projections for 2025-2027 are 1.384 billion, 1.431 billion, and 1.500 billion yuan, with growth rates of -2.02%, 3.35%, and 4.85% respectively [3] - Net profit forecasts for the same period are 122 million, 184 million, and 204 million yuan, with growth rates of -25.72%, 50.96%, and 10.73% respectively [3]

Group 1 - Huida Sanitary Ware plans to publicly transfer 100% equity and debt of Guangxi Xingaosheng, with debt amounts of 132 million and 138 million yuan as of June 30, 2025 [1] - Sainuo Medical received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate information disclosure in quarterly reports [2][3] - Jiangling Motors reported August vehicle sales of 30,003 units, a year-on-year increase of 8.92% [6] Group 2 - Jimin Health's controlling shareholder plans to reduce its stake by up to 3%, totaling 15.75 million shares [7] - Satellite Chemical announced routine maintenance of polyethylene and ethylene glycol facilities, expected to last 45 days [8] - Hubei Yihua's 200,000-ton caustic soda project has been successfully put into production [10] Group 3 - Shanghai Pharmaceuticals' Dihydroxypropyl Theophylline Injection has passed the consistency evaluation for generic drugs [13] - Ningbo Construction's subsidiaries won construction projects worth 1.117 billion yuan [16] - Wens Foodstuff reported August sales revenue of 4.825 billion yuan from live pigs, with a year-on-year decrease in revenue and price [28] Group 4 - Long-term Logistics announced the resignation of its deputy general manager due to personal reasons [44] - Huaming Equipment proposed a cash dividend of 2 yuan per 10 shares, totaling 179 million yuan [46] - Transsion Holdings plans to distribute a cash dividend of 0.8 yuan per share [49]

登录新浪财经APP 搜索【信披】查看更多考评等级 上市公司名称：湖南华纳大药厂股份有限公司 股票上市地点：上海证券交易所 股票简称：华纳药厂 股票代码：688799 信息披露义务人一姓名：徐小强 住所及通讯地址：长沙市****** 信息披露义务人二姓名：徐燕 住所及通讯地址：长沙市****** 股份变动性质：股份减持 签署日期：2025年9月3日 信息披露义务人声明 四、本次权益变动是根据本报告书所载明的资料进行的。信息披露义务人没有委托或者授权任何其他人 提供未在本报告书中列载的信息和对本报告书做出任何解释或者说明。 五、信息披露义务人保证本报告书及相关文件内容真实、准确、完整，不存在虚假记载、误导性陈述或 重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 第一节 释义 在本报告书中，除非文意另有所指，以下简称具有如下含义： 注：本报告书中数据尾差系按照四舍五入保留两位小数所致。 第二节 信息披露义务人介绍 一、信息披露义务人的基本情况 一、本报告书系信息披露义务人依据《中华人民共和国证券法》、《上市公司收购管理办法》、《公开 发行证券的公司信息披露内容与格式准则第15号——权益变动报告书》 ...

湖南华纳大药厂股份有限公司 上市公司名称：湖南华纳大药厂股份有限公司 股票上市地点：上海证券交易所 股票简称：华纳药厂 股票代码：688799 信息披露义务人一姓名：徐小强 住所及通讯地址：长沙市****** 信息披露义务人二姓名：徐燕 住所及通讯地址：长沙市****** 股份变动性质：股份减持 签署日期：2025 年 9 月 3 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》、 《上市公司 收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号——权 益变动报告书》及其他相关的法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、 《上市公司收购管理办法》、 《公开发行 证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》的规定，本 报告书已全面披露了信息披露义务人在湖南华纳大药厂股份有限公司中拥有权 益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，上述信息披露义务人没 有通过任何其他方式增加或减少其在湖南华纳大药厂股份有限公司中拥有权益 或表决权的股份。 四、本 ...

Core Viewpoint - The announcement details a change in shareholding by major shareholders of Hunan Warner Pharmaceutical Co., Ltd., specifically a reduction in shareholding by over 5% by shareholder Xu Xiaoqiang and his concerted action partner Xu Yan, which has implications for the company's governance structure and investor perception [1][6]. Group 1: Shareholding Changes - Xu Xiaoqiang reduced his shareholding from 15.57% to 15.00%, a decrease of 0.57% [1][6]. - The reduction involved the sale of 757,120 shares, representing 0.58% of the total share capital [1][6]. - The shareholding change was executed through centralized bidding transactions from September 1 to September 3, 2025 [1][6]. Group 2: Compliance and Governance - The shareholding change does not trigger mandatory tender offer obligations and does not violate any prior commitments or plans [1][6]. - The reduction in shareholding does not affect the company's status regarding its controlling shareholders or actual controllers, ensuring stability in governance [6][7]. - The company will continue to monitor compliance with relevant regulations and ensure timely disclosure of information to investors [7].

格隆汇9月3日丨华纳药厂(688799.SH)公布，公司于2025年9月3日收到信息披露义务人出具的简式权益 变动报告书，自2025年9月1日至2025年9月3日，徐小强先生通过集中竞价交易方式累计减持公司股份 757,120股，占公司总股本0.58%。徐小强先生及徐燕先生合计持股比例由15.57%减少至15.00%，持股比 例触及5%刻度线的整数倍。 ...